Safer steroid eye drops for kids? new study tests two options
NCT ID NCT07496060
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested two different steroid eye drops—loteprednol and prednisolone—in 66 children with inflammatory nodules in the front part of the eye. The goal was to see if loteprednol could control inflammation as well as prednisolone while causing fewer increases in eye pressure. Children used the drops four or six times a day and were monitored for three months.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Loteprednol etabonate 1% and prednisolone acetate 1% eye drops
- What this could lead to
- If loteprednol works as well as prednisolone but with less risk of high eye pressure, it could become a preferred treatment for this condition.
- What could go wrong
- This is a small, completed Phase 4 trial with only 66 children, so results may not apply to all patients. Both drugs are steroids and can still raise eye pressure or cause other side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
66 people
The number who actually took part.
- Started
-
Aug 2025
- Finished
-
Jan 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
4 to 21 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Any patient presenting with an active anterior chamber granuloma. * Patients must be treatment-naïve, having received no previous medical treatment for the current condition. * Willingness of the parent or legal guardian to provide written informed consent. Exclusion Criteria: * History of recurrent uveitis. * Pre-existing glaucoma or a baseline intraocular pressure greater than 21 mmHg. * Presence of a cataract. * Active corneal infection or corneal ulcer. * Active inflammation clearly attributed to trauma, lens-induced causes, or underlying rheumatologic disease. * Evidence of active posterior uveitis.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Anterior chamber granulomatous uveitis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fayoum university Hospital
Al Fayyum, Faiyum Governorate, 63514, Egypt